We speak with Clifford Hudis, MD, Memorial Sloan-Kettering Cancer Center, about the recent advances in breast cancer treatment and the top news to come out of this year’s ASCO Breast Cancer Symposium.

The 18-month results of the phase III BOLERO-2 trial were presented at the ASCO Breast Cancer Symposium, confirming earlier survival results.

Several presentations at the ASCO Breast Cancer Symposium addressed important questions in triple-negative breast cancer: are there promising new treatment approaches for these patients and how can we identify which patients are high risk?

Final results of the RIBBON-2 trial show that adding bevacizumab (Avastin) to chemotherapy does not improve overall survival in advanced breast cancer patients who have been previously treated for their metastatic disease.

A new device called MarginProbe may soon be available to help surgeons determine the minimal amount of tissue to be removed during a lumpectomy and reduce re-excision rates.

In this video, Tari A. King, MD, of the Memorial Sloan-Kettering Cancer Center, discusses what to look for at this year’s ASCO Breast Cancer Symposium.